Varo Rosauro, Chaccour Carlos, Bassat Quique
ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique; Ifakara Health Institute, Ifakara, United Republic of Tanzania; Facultad de Medicina, Universidad de Navarra, Pamplona, Spain.
Med Clin (Barc). 2020 Nov 13;155(9):395-402. doi: 10.1016/j.medcli.2020.05.010. Epub 2020 Jun 30.
Despite recent successful efforts to reduce the global malaria burden, this disease remains a significant global health problem. Only in 2018, malaria caused 228 million clinical episodes, 2-4 million of which were severe malaria cases, and 405,000 were fatal. Most of the malaria attributable mortality occurred among children in sub-Saharan Africa. Nowadays, rapid diagnostic tests and artemisinin derivatives are two of the main pillars for the management of malaria. However, considering the current situation, these strategies are not sufficient to maintain a reducing trend in malaria incidence and mortality. New insights into the pathophysiology of malaria have highlighted the importance of the host response to infection. Understanding this response would help to develop new diagnostic and therapeutic tools. Vector and parasite drug resistance are two major challenges for malaria control that require special attention. The most advanced malaria vaccine (RTS,S) is currently being piloted in 3 African countries.
尽管最近在减轻全球疟疾负担方面取得了成功,但这种疾病仍然是一个重大的全球卫生问题。仅在2018年,疟疾就导致了2.28亿例临床发作,其中200万至400万例为重症疟疾病例,40.5万人死亡。大多数疟疾所致死亡发生在撒哈拉以南非洲的儿童中。如今,快速诊断检测和青蒿素衍生物是疟疾管理的两大主要支柱。然而,考虑到当前形势,这些策略不足以维持疟疾发病率和死亡率的下降趋势。对疟疾病理生理学的新见解凸显了宿主对感染反应的重要性。了解这种反应将有助于开发新的诊断和治疗工具。病媒和寄生虫耐药性是疟疾控制需要特别关注的两大主要挑战。最先进的疟疾疫苗(RTS,S)目前正在3个非洲国家进行试点。